TY - JOUR
T1 - Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern
T2 - a cohort study
AU - Twohig, Katherine A
AU - Nyberg, Tommy
AU - Zaidi, Asad
AU - Thelwall, Simon
AU - Sinnathamby, Mary A
AU - Aliabadi, Shirin
AU - Seaman, Shaun R
AU - Harris, Ross J
AU - Hope, Russell
AU - Lopez-bernal, Jamie
AU - Gallagher, Eileen
AU - Charlett, Andre
AU - Angelis, Daniela De
AU - Presanis, Anne M
AU - Dabrera, Gavin
AU - The COVID-19 Genomics UK (COG-UK) Consortium
AU - Koshy, Cherian
AU - Ash, Amy
AU - Wise, Emma
AU - Moore, Nathan
AU - Mori, Matilde
AU - Cortes, Nick
AU - Lynch, Jessica
AU - Kidd, Stephen
AU - Fairley, Derek
AU - Curran, Tanya
AU - Mckenna, James
AU - Adams, Helen
AU - Fraser, Christophe
AU - Golubchik, Tanya
AU - Bonsall, David
AU - Hassan-ibrahim, Mohammed
AU - Malone, Cassandra
AU - Cogger, Benjamin
AU - Wantoch, Michelle
AU - Reynolds, Nicola
AU - Warne, Ben
AU - Maksimovic, Joshua
AU - Spellman, Karla
AU - Mccluggage, Kathryn
AU - John, Michaela
AU - Beer, Robert
AU - Afifi, Safiah
AU - Morgan, Sian
AU - Marchbank, Angela
AU - Smith, Darren
AU - Bashton, Matthew
AU - Young, Gregory
AU - Nelson, Andrew
AU - McCann, Clare
AU - Yew, Wen
N1 - Matthew Bashton, Darren L. Smith, Gregory R. Young, Clare McCann, Andrew Nelson and Wen Chyin Yew are members of the COVID-19 Genomics UK (COG-UK) Consortium.
Funding information: This research was funded by the Medical Research Council (MRC; authors DDA and AMP: Unit Programme number MC_UU_00002/11; author SRS: Unit Programme number MC_UU_00002/10); and via a grant from the MRC UK Research and Innovation (UKRI)/Department of Health and Social Care National Institute for Health Research (NIHR) COVID-19 rapid response call (authors TN, AC, DDA, and AMP: grant reference MC_PC_19074). The COG-UK consortium is supported by funding from the MRC part of UKRI, the NIHR and Genome Research Limited, operating as the Wellcome Sanger Institute.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - BackgroundThe SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated with more severe disease than the previously dominant alpha (B.1.1.7) variant. We aimed to characterise the severity of the delta variant compared with the alpha variant by determining the relative risk of hospital attendance outcomes.MethodsThis cohort study was done among all patients with COVID-19 in England between March 29 and May 23, 2021, who were identified as being infected with either the alpha or delta SARS-CoV-2 variant through whole-genome sequencing. Individual-level data on these patients were linked to routine health-care datasets on vaccination, emergency care attendance, hospital admission, and mortality (data from Public Health England's Second Generation Surveillance System and COVID-19-associated deaths dataset; the National Immunisation Management System; and NHS Digital Secondary Uses Services and Emergency Care Data Set). The risk for hospital admission and emergency care attendance were compared between patients with sequencing-confirmed delta and alpha variants for the whole cohort and by vaccination status subgroups. Stratified Cox regression was used to adjust for age, sex, ethnicity, deprivation, recent international travel, area of residence, calendar week, and vaccination status.FindingsIndividual-level data on 43 338 COVID-19-positive patients (8682 with the delta variant, 34 656 with the alpha variant; median age 31 years [IQR 17–43]) were included in our analysis. 196 (2·3%) patients with the delta variant versus 764 (2·2%) patients with the alpha variant were admitted to hospital within 14 days after the specimen was taken (adjusted hazard ratio [HR] 2·26 [95% CI 1·32–3·89]). 498 (5·7%) patients with the delta variant versus 1448 (4·2%) patients with the alpha variant were admitted to hospital or attended emergency care within 14 days (adjusted HR 1·45 [1·08–1·95]). Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients with the delta variant versus the alpha variant (adjusted HR for hospital admission 1·94 [95% CI 0·47–8·05] and for hospital admission or emergency care attendance 1·58 [0·69–3·61]) were similar to the HRs for unvaccinated patients (2·32 [1·29–4·16] and 1·43 [1·04–1·97]; p=0·82 for both) but the precision for the vaccinated subgroup was low.InterpretationThis large national study found a higher hospital admission or emergency care attendance risk for patients with COVID-19 infected with the delta variant compared with the alpha variant. Results suggest that outbreaks of the delta variant in unvaccinated populations might lead to a greater burden on health-care services than the alpha variant.
AB - BackgroundThe SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high transmissibility. It is suspected that the delta variant is associated with more severe disease than the previously dominant alpha (B.1.1.7) variant. We aimed to characterise the severity of the delta variant compared with the alpha variant by determining the relative risk of hospital attendance outcomes.MethodsThis cohort study was done among all patients with COVID-19 in England between March 29 and May 23, 2021, who were identified as being infected with either the alpha or delta SARS-CoV-2 variant through whole-genome sequencing. Individual-level data on these patients were linked to routine health-care datasets on vaccination, emergency care attendance, hospital admission, and mortality (data from Public Health England's Second Generation Surveillance System and COVID-19-associated deaths dataset; the National Immunisation Management System; and NHS Digital Secondary Uses Services and Emergency Care Data Set). The risk for hospital admission and emergency care attendance were compared between patients with sequencing-confirmed delta and alpha variants for the whole cohort and by vaccination status subgroups. Stratified Cox regression was used to adjust for age, sex, ethnicity, deprivation, recent international travel, area of residence, calendar week, and vaccination status.FindingsIndividual-level data on 43 338 COVID-19-positive patients (8682 with the delta variant, 34 656 with the alpha variant; median age 31 years [IQR 17–43]) were included in our analysis. 196 (2·3%) patients with the delta variant versus 764 (2·2%) patients with the alpha variant were admitted to hospital within 14 days after the specimen was taken (adjusted hazard ratio [HR] 2·26 [95% CI 1·32–3·89]). 498 (5·7%) patients with the delta variant versus 1448 (4·2%) patients with the alpha variant were admitted to hospital or attended emergency care within 14 days (adjusted HR 1·45 [1·08–1·95]). Most patients were unvaccinated (32 078 [74·0%] across both groups). The HRs for vaccinated patients with the delta variant versus the alpha variant (adjusted HR for hospital admission 1·94 [95% CI 0·47–8·05] and for hospital admission or emergency care attendance 1·58 [0·69–3·61]) were similar to the HRs for unvaccinated patients (2·32 [1·29–4·16] and 1·43 [1·04–1·97]; p=0·82 for both) but the precision for the vaccinated subgroup was low.InterpretationThis large national study found a higher hospital admission or emergency care attendance risk for patients with COVID-19 infected with the delta variant compared with the alpha variant. Results suggest that outbreaks of the delta variant in unvaccinated populations might lead to a greater burden on health-care services than the alpha variant.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - COVID-19/epidemiology
KW - Child
KW - Child, Preschool
KW - Cohort Studies
KW - Emergency Medical Services/statistics & numerical data
KW - England/epidemiology
KW - Female
KW - Hospitalization/statistics & numerical data
KW - Humans
KW - Male
KW - Middle Aged
KW - Proportional Hazards Models
KW - SARS-CoV-2/classification
KW - Severity of Illness Index
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85121754161&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(21)00475-8
DO - 10.1016/S1473-3099(21)00475-8
M3 - Article
C2 - 34461056
SN - 1473-3099
VL - 22
SP - 35
EP - 42
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 1
ER -